You are here: Industry Insights > chemotherapy

News List

A Glimpse of the Oncology Drug Treatment Market in China PharmaSources/Xiaoyaowan
May 31, 2021
According to statistics, the market size of China’s oncology treatment industry reached RMB387.6 billion in 2020, with a compound annual growth rate of 10.3% in the past five years as compared to RMB261.4 billion in 2016, and this market size is expected
European Commission Approves KEYTRUDA Plus LENVIMA for Patients With Endometrial Carcinoma AmericanPharmaceuticalReview
December 02, 2021
Merck and Eisai announced that the European Commission has approved the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for the treatment of advance...
Imfinzi Approved in China for Small Cell Lung Cancer americanpharmaceuticalreview
July 20, 2021
AstraZeneca’s Imfinzi (durvalumab) has been approved in China for the 1st-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with standard of care platinum chemotherapy (etoposide plus a choice of ...
Using personalized medicine to avoid resistance to leukemia treatment worldpharmanews
May 11, 2021
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20.
Chemotherapy uptake to gradually decrease with arrival of novel therapies and biosimilars- GlobalData expresspharma
March 26, 2021
Trends in chemotherapy sales are expected to vary widely with CAGRs ranging from -14.92 per cent to 8.40 per cent across 15 major.
FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy americanpharmaceuticalreview
February 22, 2021
The U.S. Food and Drug Administration (FDA) approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage ...
ICR urges change as NICE rejects Keytruda plus chemotherapy pharmatimes
October 26, 2020
The Institute for Cancer Research (ICR) has called for change in the way immunotherapy drugs are researched and evaluated after the National Institute for Health and Care Excellence (NICE) handed MSD’s Keytruda plus chemotherapy a rejection.
Avelumab significantly improves advanced bladder cancer patient survival europeanpharmaceuticalreview
September 22, 2020
A Phase III trial concluded that avelumab is an effective maintenance therapy for patients with advanced or metastatic urothelial carcinoma, whose disease had not progressed after chemotherapy.
Post-surgery chemo halves risk of recurring rare kidney cancer pharmatimes
March 09, 2020
A new trial has revealed that chemotherapy after surgery can reduce the risk of cancer of the ureter and renal pelvis returning by half.
Microcapsules provide targeted chemotherapy drug delivery to cancer cells europeanpharmaceuticalreview
December 12, 2019
Development of infrared light-sensitive microcapsules could be the future in targeted drug delivery for cancer treatment, says new research.

Previous page 1 2 3 4 5 Next page